# Astal  Lab (NSE: ASTALLTD) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ASTALLTD · Pivot · prices to 21 Oct 2026

With a market capitalisation of ₹358 Cr, it ranks 1969th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 24.8% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹134 Cr (+471.2% year on year) and net profit ₹8 Cr (+180.3%), on a consolidated basis. Promoters held 4.53% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹358 Cr |
| ROE | 24.8% (FY25) |
| ROCE | 34.7% (FY25) |
| Debt to equity | 0.37 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹134 Cr | +471.2% | ₹8 Cr | +180.3% | ₹2.04 |
| Q3 FY26 | ₹52 Cr | — | ₹2 Cr | — | ₹2.19 |
| Q4 FY25 | ₹23 Cr | — | ₹3 Cr | — | ₹2.80 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹64 Cr | ₹9 Cr |
| FY24 | ₹24 Cr | ₹1 Cr |
| FY23 | ₹3 Cr | ₹0 Cr |
| FY22 | ₹0 Cr | −₹0 Cr |
| FY21 | ₹0 Cr | ₹0 Cr |
| FY20 | ₹0 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 4.53%
- Non-institutions: 95.47%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Jenburkt Pharma](https://app.pivotnow.in/stock/JENBURPH) | ₹902.75 | ₹398 Cr | 11.5 | — |
| [Transchem](https://app.pivotnow.in/stock/TRANSCHEM) | — | ₹391 Cr | — | — |
| [Aptus Pharma](https://app.pivotnow.in/stock/APPL) | — | ₹377 Cr | — | — |
| [Medicamen Biotech](https://app.pivotnow.in/stock/MEDICAMEQ) | ₹267.20 | ₹362 Cr | 37 | — |
| [Aarey Drugs & Pharmaceuticals](https://app.pivotnow.in/stock/AAREYDRUGS) | ₹111.83 | ₹317 Cr | 80.5 | — |
| [Lyka Labs](https://app.pivotnow.in/stock/LYKALABS) | ₹86.04 | ₹311 Cr | — | — |

## Questions and answers

### What is the market cap of Astal  Lab?

Astal  Lab's market capitalisation is ₹358 Cr (₹358 Cr) at the 21 Oct 2026 close, ranking 1969th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Astal  Lab?

Return on equity was 24.8% in FY25 and return on capital employed was 34.7% in FY25 (standalone figures).

### Is Astal  Lab a debt-free company?

No. Astal  Lab's debt-to-equity ratio was 0.37 in FY25, with total debt of ₹0 Cr.

### What were Astal  Lab's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Astal  Lab reported revenue of ₹134 Cr, +471.2% year on year, and net profit of ₹8 Cr, +180.3% year on year.

### What is the shareholding pattern of Astal  Lab?

As of 30 Jun 2026: promoters 4.53%, non-institutions 95.47%.

### Who are Astal  Lab's competitors?

The listed Pharma & Healthcare companies closest to Astal  Lab by market cap are Jenburkt Pharma, Transchem, Aptus Pharma, Medicamen Biotech, Aarey Drugs & Pharmaceuticals and Lyka Labs.

### Is Astal  Lab a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Astal  Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTALLTD against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.